To observe the impact of Yupingfengsan Oral Liquid on the expression of IL-4 and IFN-<em>γ</em> in AR mice’s serum and expression level of nuclear factor—<em>κ</em>B (NF-<em>κ</em...To observe the impact of Yupingfengsan Oral Liquid on the expression of IL-4 and IFN-<em>γ</em> in AR mice’s serum and expression level of nuclear factor—<em>κ</em>B (NF-<em>κ</em>B) protein and gene in nasal mucosa. <strong>Method:</strong> Forty BALB/c mice were randomly divided into the normal group, model group, Yupingfengsan Oral Liquid group (6 g/kg) and Loratadine group, with 10 mice per group. AR mice model was established by OVA, and IL-4 and IFN-<em>γ</em> contents can be measured with ELISA. The morphological changes of nasal mucosa were observed by hematoxylin eosin (HE) staining and NF-<em>κ</em>B expression in the nasal mucosa of mice was tested with Real-Time PCR and Western blot. <strong>Results:</strong> Compared with the model group, the nasal symptoms in the Yupingfengsan Oral Liquid group and Loratadine group were obviously relieved. HE staining showed that there was a little inflammatory cell infiltration in the nasal mucosa of Yupingfengsan Oral Liquid group and Loratadine group and it was significantly reduced when compared with the model group. IL-4 level in the serum and expression of NF-<em>κ</em>B protein and gene in the nasal mucosa was consistent and it was decreased when compared with the model group (P < 0.01), but the IFN-<em>γ</em> level in the serum was increased (P < 0.01). <strong>Conclusion:</strong> Yupingfengsan Oral Liquid can improve the clinical symptoms and histopathological manifestations of AR mice sensitized by OVA, inhibit the NF-<em>κ</em>B expression, balance the percentage of Th1/Th2 cells, increase the IFN-<em>γ</em> level in the serum and decrease the IL-4 level.展开更多
文摘To observe the impact of Yupingfengsan Oral Liquid on the expression of IL-4 and IFN-<em>γ</em> in AR mice’s serum and expression level of nuclear factor—<em>κ</em>B (NF-<em>κ</em>B) protein and gene in nasal mucosa. <strong>Method:</strong> Forty BALB/c mice were randomly divided into the normal group, model group, Yupingfengsan Oral Liquid group (6 g/kg) and Loratadine group, with 10 mice per group. AR mice model was established by OVA, and IL-4 and IFN-<em>γ</em> contents can be measured with ELISA. The morphological changes of nasal mucosa were observed by hematoxylin eosin (HE) staining and NF-<em>κ</em>B expression in the nasal mucosa of mice was tested with Real-Time PCR and Western blot. <strong>Results:</strong> Compared with the model group, the nasal symptoms in the Yupingfengsan Oral Liquid group and Loratadine group were obviously relieved. HE staining showed that there was a little inflammatory cell infiltration in the nasal mucosa of Yupingfengsan Oral Liquid group and Loratadine group and it was significantly reduced when compared with the model group. IL-4 level in the serum and expression of NF-<em>κ</em>B protein and gene in the nasal mucosa was consistent and it was decreased when compared with the model group (P < 0.01), but the IFN-<em>γ</em> level in the serum was increased (P < 0.01). <strong>Conclusion:</strong> Yupingfengsan Oral Liquid can improve the clinical symptoms and histopathological manifestations of AR mice sensitized by OVA, inhibit the NF-<em>κ</em>B expression, balance the percentage of Th1/Th2 cells, increase the IFN-<em>γ</em> level in the serum and decrease the IL-4 level.
文摘目的比较变应性鼻炎(allergic rhinitis,AR)患者接受标准化尘螨变应原疫苗皮下免疫治疗(subcutaneous immunotherapy,SCIT)和舌下免疫治疗(sublingual immunotherapy,SLIT)的疗效及对患者生活质量的改善程度。方法 96例尘螨过敏的中-重度持续性AR患者纳入本研究,分别采用SCIT和SLIT方案,完成2年的特异性免疫治疗。其中SCIT组46例、SLIT组50例。比较两组治疗前后症状评分(VAS评分)、药物用量评分以及疾病专用量表-鼻结膜炎生存质量调查问卷(rhinoconjunctivitis quality of life questionnaire,RQLQ)评分,评价各组的疗效和对患者生活质量的改善程度,并观察两组的不良反应发生率。结果治疗2年后,SCIT组和SLIT组患者的喷嚏、流涕、鼻塞和鼻痒症状以及鼻部症状总评分(VAS评分)、药物用量评分均明显下降,SCIT治疗对减少药物使用的效果较显著,同SLIT组比较,差异有统计学意义(P<0.05)。治疗后两组患者的RQLQ评分均有下降,尤其在鼻部症状和实际问题这2个维度评分下降明显,与其他维度相比,差异有统计学意义(P<0.05)。结论尘螨过敏的中-重度持续性AR患者采用SCIT或SLIT进行为期2年的特异性免疫治疗均能获得良好效果,改善患者生活质量的程度未见明显差异,但是SCIT治疗能减少药物的使用。
文摘目的通过Meta分析探讨鼻内镜下鼻后神经切断术(PNN)与其他方法治疗中重度变应性鼻炎(AR)的临床疗效和安全性,为PNN的临床实践提供循证医学参考。方法通过计算机检索,检索时间为数据库建立至2021年9月,从Pubmed、Sinomed、Cochrane Library、Web of Science、Embase、维普数据库、中国知网、万方数据库中检索相关文献及其参考文献。由两人独立对文献进行筛选,提取数据资料并评价文献质量,采用Revman 5.3软件对文献原始数据进行Meta分析。结果通过上述方法,筛选出了9篇文献,包含523名患者。Meta分析结果显示,除高选择性翼管神经切断术(鼻后神经+翼管神经咽支切断,HSVN)外,PNN较其他治疗方法都能明显降低中重度AR患者的鼻结膜炎生存质量调查问卷(RQLQ)和/或症状视觉模拟量表(VAS)评分,差异有统计学意义(P<0.05),而并发症发生率差异无统计学意义(P>0.05)。与药物治疗比较,PNN能显著提高患者的有效率[RR=2.01,95%CI(1.64,2.45),P<0.05];而与功能性鼻内镜手术(FESS)联合可获得更好的有效率[RR=1.57,95%CI(1.29,1.90),P<0.05];当PNN与HSVN相比时,两组之间总的有效率相当[RR=1.04,95%CI(0.95,1.13),P=0.4],两组患者鼻部症状的VAS评分差异无统计学意义(P>0.05),但对于咳嗽和/或咽痒症状来说,HSVN的VAS评分更低(P<0.05),说明两种手术方式对鼻部主要症状的改善相当,但对于合并有咳嗽和/或咽痒症状的患者来说,HSVN手术效果更明显。结论PNN对于中重度AR是一种疗效与安全性较理想的治疗方法。但对于合并咳嗽和/或咽痒症状的患者来说,HSVN可获得更好的疗效,并且安全性也相当。
